Get the Stockscreener App
14.59
2.08%
-0.31
After Hours:
14.99
0.40
+2.74%
Mink Therapeutics Inc stock is traded at $14.59, with a volume of 31,695.
It is down -2.08% in the last 24 hours and down -7.83% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
See More
Previous Close:
$14.90
Open:
$14.36
24h Volume:
31,695
Relative Volume:
0.03
Market Cap:
$65.99M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-19.99
EPS:
-0.73
Net Cash Flow:
$-17.36M
1W Performance:
-0.48%
1M Performance:
-7.83%
6M Performance:
+86.81%
1Y Performance:
+115.19%
1-Day Range:
$14.32
$15.35
1-Week Range:
$14.10
$16.00
52-Week Range:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
14.59 | 67.39M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
Will MiNK Therapeutics Inc. (6Q40) stock see insider accumulationJuly 2025 Momentum & Weekly Stock Performance Updates - newser.com
How to escape a deep drawdown in MiNK Therapeutics Inc.Fed Meeting & Real-Time Sentiment Analysis - newser.com
Why MiNK Therapeutics Inc. stock is popular among millennialsJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Is MiNK Therapeutics Inc. (6Q40) stock undervalued historicallyAnalyst Upgrade & Weekly Return Optimization Plans - newser.com
Tools to assess MiNK Therapeutics Inc.’s risk profileJuly 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
MiNK Therapeutics Inc. stock prediction for this weekQuarterly Market Summary & Technical Pattern Recognition Alerts - newser.com
Evaluating MiNK Therapeutics Inc. with trendline analysisQuarterly Earnings Summary & High Yield Stock Recommendations - newser.com
How MiNK Therapeutics Inc. (6Q40) stock moves in volatile trading sessions2025 Top Decliners & Free Low Drawdown Momentum Trade Ideas - newser.com
Risk vs reward if holding onto MiNK Therapeutics Inc.2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
What analysts say about MiNK Therapeutics Inc stockFundamental Stock Analysis & Fast Profit Portfolio Plans - earlytimes.in
Published on: 2025-10-03 05:09:10 - earlytimes.in
LakeShore Biopharma (NASDAQ:LSB) & MiNK Therapeutics (NASDAQ:INKT) Financial Survey - Defense World
What analysts say about MiNK Therapeutics Inc 6Q40 stockQuarterly Earnings Review & Free Discover Massive Upside Stocks - earlytimes.in
MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board - Investing.com
MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board By Investing.com - Investing.com South Africa
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, FACS to Board of Directors - Quiver Quantitative
MiNK Therapeutics appoints Colonel (Ret.) John B. Holcomb to board of directors - MarketScreener
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors - GlobeNewswire
Military Medicine Legend with 780 Publications: MiNK Therapeutics Adds Combat Care Pioneer to Board - Stock Titan
MiNK Therapeutics Inc Stock Analysis and ForecastVolatility Index Analysis & Maximum Capital Growth - earlytimes.in
What drives MiNK Therapeutics Inc stock priceHigh Yield Income Stocks & Free Quantitative Trading Strategies - Early Times
MiNK Therapeutics CEO Dr. Jennifer Buell to Present at 10th Annual CAR-TCR Summit on iNKT Cell Therapies - Quiver Quantitative
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA - GlobeNewswire
First-in-Human Results: MiNK's Off-the-Shelf Cell Therapy Shows Disease Reversal in Immune Disorders - Stock Titan
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):